TW200800158A - Methods for neuroprotection - Google Patents

Methods for neuroprotection Download PDF

Info

Publication number
TW200800158A
TW200800158A TW095125161A TW95125161A TW200800158A TW 200800158 A TW200800158 A TW 200800158A TW 095125161 A TW095125161 A TW 095125161A TW 95125161 A TW95125161 A TW 95125161A TW 200800158 A TW200800158 A TW 200800158A
Authority
TW
Taiwan
Prior art keywords
group
formula
substituted
disease
soil
Prior art date
Application number
TW095125161A
Other languages
English (en)
Chinese (zh)
Inventor
Roy E Twyman
Boyu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200800158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200800158A publication Critical patent/TW200800158A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095125161A 2005-07-12 2006-07-11 Methods for neuroprotection TW200800158A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69840305P 2005-07-12 2005-07-12

Publications (1)

Publication Number Publication Date
TW200800158A true TW200800158A (en) 2008-01-01

Family

ID=37637734

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095125161A TW200800158A (en) 2005-07-12 2006-07-11 Methods for neuroprotection

Country Status (18)

Country Link
US (2) US20070021500A1 (https=)
EP (1) EP1917009A2 (https=)
JP (1) JP2009501224A (https=)
KR (1) KR20080031951A (https=)
CN (1) CN101287459A (https=)
AR (1) AR054551A1 (https=)
AU (1) AU2006269381A1 (https=)
BR (1) BRPI0613006A2 (https=)
CA (1) CA2615129A1 (https=)
CR (1) CR9721A (https=)
EA (1) EA200800294A1 (https=)
EC (1) ECSP088179A (https=)
IL (1) IL188729A0 (https=)
NI (1) NI200800008A (https=)
NO (1) NO20080738L (https=)
TW (1) TW200800158A (https=)
WO (1) WO2007008562A2 (https=)
ZA (1) ZA200801401B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005335241B9 (en) * 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
EP1996284A2 (en) * 2006-03-09 2008-12-03 Synapse Biomedical, Inc. Ventilatory assist system and method to improve respiratory function
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
CN101657195A (zh) * 2006-10-06 2010-02-24 詹森药业有限公司 氨基甲酸(s)-(+)-2-(2-氯代苯基)-2-羟基乙酯的新型晶体
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
WO2008144578A1 (en) * 2007-05-17 2008-11-27 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
US8478412B2 (en) * 2007-10-30 2013-07-02 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
KR101418061B1 (ko) * 2012-09-28 2014-07-10 한국과학기술연구원 성상교세포의 글루타메이트 방출 기작
US9566261B2 (en) 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
ES3059582T3 (en) 2016-02-29 2026-03-23 Bio Pharm Solutions Co Ltd Sulfamate derivative compounds, processes for preparing them and their uses
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
JP2023539291A (ja) * 2020-08-31 2023-09-13 バイオ－ファーム ソリューションズ カンパニー リミテッド 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
PL213323B1 (pl) * 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie
PL364680A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
CA2580640A1 (en) * 2004-09-16 2006-03-30 Janssen Pharmaceutica N.V. Methods of treating epileptogensis and epilepsy
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato

Also Published As

Publication number Publication date
IL188729A0 (en) 2008-11-03
KR20080031951A (ko) 2008-04-11
CA2615129A1 (en) 2007-01-18
AR054551A1 (es) 2007-06-27
EA200800294A1 (ru) 2008-06-30
NI200800008A (es) 2010-11-25
ZA200801401B (en) 2009-08-26
US20070021500A1 (en) 2007-01-25
AU2006269381A1 (en) 2007-01-18
EP1917009A2 (en) 2008-05-07
JP2009501224A (ja) 2009-01-15
US20090137652A1 (en) 2009-05-28
ECSP088179A (es) 2008-03-26
WO2007008562A3 (en) 2007-08-16
CN101287459A (zh) 2008-10-15
BRPI0613006A2 (pt) 2010-12-14
WO2007008562A2 (en) 2007-01-18
CR9721A (es) 2008-11-24
NO20080738L (no) 2008-04-10

Similar Documents

Publication Publication Date Title
TW200800158A (en) Methods for neuroprotection
ES2979034T3 (es) Procedimientos de tratamiento del síndrome de Lennox-Gastaut mediante el uso de fenfluramina
JP2010528016A (ja) 細胞を刺激するための方法および組成物
AU2005304352A1 (en) Method for treatment of movement disorders
EP2254598A2 (en) Alpha 7 nicotinic agonists and antipsychotics
CN107441104B (zh) 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
IL261669B1 (en) A combination of thyroid hormones and a rxr agonist for the treatment of autoimmune diseases
JP7429942B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
CA3103463A1 (en) Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
TW200418460A (en) Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
JP2010501581A (ja) 神経細胞の損傷を減少させる方法
Zang et al. Electroconvulsive therapy combined with esketamine improved depression through PI3K/AKT/GLT-1 pathway
CN106389740A (zh) 一种预防和/或延缓老年轻度认知障碍的组合物及其使用方法
JP7134097B2 (ja) 神経障害性疼痛の治療のための低用量ｆｌｔ３受容体阻害剤
ES2935705T3 (es) Un ligando del receptor GABA A
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
CN102858176A (zh) 镇痛化合物、组合物及其应用
CN116098918B (zh) 一种胞磷胆碱药物组合物及其用途
KR20080080094A (ko) 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
Barr et al. Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats
Poniatowski et al. Dose-ranging effects of the intracerebral administration of atsttrin in experimental model of Parkinson’s disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice
JP6522641B2 (ja) 機械的な神経損傷を処置するための新規組成物
ES2808667T3 (es) Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta
CN107441105A (zh) 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用